Catherine Alix-Panabieres,
Associate Professor,
University Medical Center of Montpellier
Dr Catherine Alix-Panabières received her PhD degree in 1998 at the Institute of Virology, University Louis Pasteur, in Strasbourg (France). In 1999, she moved to Montpellier where she did a postdoctoral research in the Department of Immuno-Virology of the University Medical Centre of Montpellier, France. During this last decade, Dr Alix-Panabières has focused on optimizing new techniques of enrichment and detection of viable disseminating tumour cells in patients with solid tumors. She is the expert for the EPISPOT technology which is used to detect viable tumor cells in the peripheral blood and the bone marrow of patients with breast, prostate and colon cancer. She is an associate-professor in the Laboratory of Cellular and Hormonal Biology at the University Medical Center of Montpellier and recently, she built a new laboratory (Laboratory of Rare Human Circulating cells - Institute of Research in Biotherapy – University Medical Centre Montpellier, France, http://irb.chu-montpellier.fr/index.html). Responsible of the Cancer Research department, they isolate, detect and characterize CTC/DTC using combination of the EPISPOT assay, the CellSearch® system (Veridex) and the last generation of a high tech flow cytometer (MoFlo-Astrios - Beckmann Coulter). She has authored or co-authored 25 scientific publications in this field during the last 5 years including 9 book chapters.
Liquid Biopsy in Cancer Patients: A focus on Metastasis-Initiator Circulating Tumor Cells
Wednesday, 9 October 2019 at 14:30
Add to Calendar ▼2019-10-09 14:30:002019-10-09 15:30:00Europe/LondonLiquid Biopsy in Cancer Patients: A focus on Metastasis-Initiator Circulating Tumor CellsSingle Cell Analysis Summit 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
Circulating tumor cells (CTCs) in blood are promising new biomarkers potentially useful for prognostic prediction and monitoring of therapies in patients with solid tumors including colon cancer. Moreover, CTC research opens a new avenue for understanding the biology of metastasis in cancer patients. However, an in-depth investigation of CTCs is hampered by the very low number of these cells, especially in the blood of colorectal cancer patients. Thus, the establishment of cell cultures and permanent cell lines from CTCs has become the most challenging task over the past year.
We described, for the first time, the establishment of cell cultures and a permanent cell line from CTCs of one colon cancer patient (Cayrefourcq et al.Cancer Res. 2015). The cell line designated CTC-MCC-41 is in culture for more than three years and has been characterized at the genome, transcriptome, proteome and secretome levels. This thorough analysis showed that CTC-MCC-41 cells resemble characteristics of the original tumor cells in the colon cancer patient and display a stable phenotype characterized by an intermediate epithelial/mesenchymal phenotype, stem-cell like properties and an osteomimetic signature indicating a bone marrow origin. Functional studies showed that CTC-MCC-41 cells induced rapidly in vitroendothelial cell tube formation and in vivotumors after xenografting in immunodeficient mice. In 2017, we defined the molecular portrait of these metastasis-competent CTCs (Alix-Panabières et al. Clin Chem. 2017). These results highlight that CTC-MCC-41 line display a very specific transcription program completely different than those of the primary and metastatic colon cancer cell lines.More recently, we characterized 8 additional CTC lines using blood samples from the same metastatic cancer: a unique biological material collected before and after chemotherapy and targeted therapy, and during cancer progression (Soler et al. Sci. Rep. 2018).
Such data may supply insights for the discovery of new biomarkers to identify the most aggressive CTC sub-populations and for the development of new drugs to inhibit metastasis-initiator CTCs in colon cancer.
Add to Calendar ▼2019-10-09 00:00:002019-10-09 00:00:00Europe/LondonSingle Cell Analysis Summit 2019Single Cell Analysis Summit 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2019-10-09 14:30:002019-10-09 15:30:00Europe/LondonLiquid Biopsy in Cancer Patients: A focus on Metastasis-Initiator Circulating Tumor CellsSingle Cell Analysis Summit 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
